IgA nephropathy trials in France

In France 12 Also abroad 92

12 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Where
Bron, Nantes, Paris, Toulouse
Age
2 years to 18 years
People
28 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07498335
Phase 3Taking people
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Where
Bordeaux, Creteil, Limoges, Montpellier, Nantes, Paris
Age
18 years and over
People
347 worldwide
Run by
Takeda
See details and how to joinNCT06963827 · EU 2025-520825-19-00
Phase 3Taking people
A clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have completed previous zigakibart trials
Where
Grenoble Cedex 9, Lille, Lyon Cedex 03, Paris
Age
18 years and over
People
69 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-519638-22-00 · EU 2024-519638-22-00
Phase 3Taking people
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Where
Amiens Cedex 1, Besançon, Bordeaux, Creteil Cedex, La Roche Sur Yon Cedex 9, Mulhouse, Nimes Cedex 9, Orleans Cedex 2, Paris, Reims, Strasbourg, Suresnes
Age
18 years and over
People
454 worldwide
Run by
Biogen
See details and how to joinNCT06935357 · EU 2024-519345-30-00
Phase 2Taking people
Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study
Where
Bordeaux, Clermont-Ferrand, Epagny Metz-tessy, Grenoble Cedex 9, Limoges, Lyon Cedex 03, Marseille, Nantes, Nimes Cedex 9, Paris, Paris Cedex 18, Paris Cedex 20, Pierre-Bénite, Rennes, Saint-Priest-en-Jarez, Strasbourg Cedex, Thionville, Valenciennes
Age
18 years and over
People
334
Run by
Centre Hospitalier Universitaire de Saint Etienne
See details and how to joinNCT06350630 · EU 2024-512653-25-00
Phase 3Taking people
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Where
Marseille, Montpellier Cedex 5, Paris
Age
18 years to 100 years
People
540 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04557462 · EU 2023-508690-92-00
No phaseTaking people
Study of the Link Between Complement Activation and IgA Nephropathy Severity
Where
Strasbourg
Age
18 years and over
People
400
Run by
University Hospital, Strasbourg, France
See details and how to joinNCT05234463
No phaseTaking people
Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
Where
Paris
Age
18 years to 90 years
People
146
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT07010250
No phaseTaking people
RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)
Where
Paris
Age
18 years and over
People
800
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT06926244
Phase 2/3Enrolling by invitation
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
Where
Grenoble, Limoges, Nantes, Nîmes, Sr Priest En Jarez
Age
18 years and over
People
600 worldwide
Run by
Otsuka Pharmaceutical Development & Commercialization, Inc.
See details and how to joinNCT05248659
No phaseTaking people
Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN)
Where
Limoges
Age
18 years and over
People
150
Run by
University Hospital, Limoges
See details and how to joinNCT07295808
No phaseTaking people
Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy
Where
Besançon
Age
18 years and over
People
75
Run by
Centre Hospitalier Universitaire de Besancon
See details and how to joinNCT05791162